Cancer immunotherapy is a validated and critically important approach for treating patients
with cancer. Given the vast research and clinical investigation efforts dedicated to advancing …

Gliomas are intrinsic brain tumors that originate from neuroglial progenitor cells.
Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved …

Immuno-oncology approaches have entered clinical practice, with tremendous progress
particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide …

Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities
has become a promising strategy in clinical management of hematologic malignancies. The …

Cytotoxic chemotherapeutics primarily function through DNA damage-induced tumor cell
apoptosis, although the inflammation provoked by these agents can stimulate anti-cancer …

Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have yielded
unprecedented efficacy in B cell malignancies, most remarkably in anti-CD19 CAR-T cells …

The redirection of T cells against tumors holds much promise for the treatment of cancer.
Two main approaches for T-cell redirection involve their genetic modification with chimeric …

Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up
a wide range of applications, including redirecting T cells to tumor cells, blocking two …

The recent advances in the field of immuno-oncology have dramatically changed the
therapeutic strategy against advanced malignancies. Bispecific antibody-based …

Blinatumomab, a bispecific antibody that directs CD3+ T cells to CD19+ tumor cells, shows
variable efficacy in B-progenitor acute lymphoblastic leukemia (B-ALL). To determine tumor …